Oral propranolol in the treatment of infantile hemangioma: a case series of 50 infants

Martínez Roca, C.; Rodríguez Ruíz, M.; Vilaboa Pedrosa, C.; Gómez Tellado, M.; Del Pozo Losada, J.; Martín Herranz, M. I.
April 2014
European Journal of Pediatric Dermatolgy;Apr-Jun2014, Vol. 24 Issue 2, p86
Academic Journal
The aim of this study was to analyse the effectiveness and safety of oral propranolol in the off-label treatment of infantile hemangioma. A retrospective observational study carried out between August 2008 and June 2013 included all the patients diagnosed with infantile hemangioma who were prescribed propranolol. The data obtained were as follows: age, sex, diagnosis, risk factors, dose regimen, duration of treatment, effectiveness, side effects and clinical course in the six months after the end of treatment. Propranolol was prescribed to 50 children without cardiopulmonary risk factors and with suitable blood sugar levels. The initial dose of 0.5 mg/kg per day was gradually increased every 3 days to a maximum of 2 mg/kg/day. In all of the cases, the total daily dose was administered twice, every 12 hours. 94% of the patients responded to treatment. The remaining 6% did not respond to propranolol, even when the dose was increased. In the patients who responded to treatment, shrinkage of the tumor was observed in the first 3-7 days. The mean duration of treatment was 9.2 months. In two cases, tumor re-growth was observed after treatment was stopped. During the study period, 4 slight side effects were observed: 3 altered sleep patterns and 1 bronchospasm associated with a viral process.


Related Articles

  • A prospective study to assess the efficacy and safety of oral propranolol as first-line treatment for infantile superficial hemangioma. Yeong Ju Yun; Yun Hee Gyon; Sohyoung Yang; Youn Kyung Lee; Joohyun Park; Meerim Park // Korean Journal of Pediatrics;2015, Vol. 58 Issue 12, p484 

    Purpose: To determine the efficacy and safety of oral propranolol as a first-line treatment for superficially located infantile hemangioma (IH) and propose an assessment tool to measure treatment response. Methods: Patients with superficial IH under 1 year of age were prospectively recruited...

  • 'Provisional' guidelines available for propranolol in infantile hemangioma. Cox, Amber; Zacharyczuk, Colleen // Infectious Diseases in Children;Feb2013, Vol. 26 Issue 2, p22 

    The article reports on the provisional guidelines published for the use of propranolol in the treatment of infantile hemangioma.

  • Propranolol.  // Reactions Weekly;2/6/2016, Vol. 1587 Issue 1, p234 

    An abstract of the article "Treatment for Infantile Hemangiomas: Selection Criteria, Safety, and Outcomes Using Oral Propranolol During the Early Phase of Propranolol Use for Hemangiomas" by Z.M. MacIsaac and others is presented.

  • PROPRANOLOL IN THE TREATMENT OF SUBGLOTTIC HAEMANGIOMA. HALILBAŠIĆ, Amir; HOTIĆ, Nešad; HUSARIĆ, Edin; PAŠIĆ, Amela; SULJENDIĆ, Sanimir // Pedijatrija Danas: Pediatrics Today;2014, Vol. 10 Issue 2, p159 

    Objective -- Subglottic infantile haemangioma (SGH) is a rare but potentially life-threatening disease. We describe a case of successful treatment with propranolol of a severely respiratory compromised 2-month-old infant with an obstructing SGH. Case report -- A fullterm 2-month-old male infant,...

  • Oral propranolol for infantile haemangioma.  // Africa Health;Jul2015, Vol. 37 Issue 5, p36 

    The article discusses a research concerning the efficacy of propranolol as treatment for infantile haemangiomas, a common soft-tissue tumours of childhood.

  • Hemangiol cost effective for proliferating infantile haemangioma.  // PharmacoEconomics & Outcomes News;Aug2015, Vol. 735 Issue 1, p16 

    The article reviews the report "Cost-utility Analysis of Propranolol versus Corticosteroids in the Treatment of Proliferating Infantile Hemangioma in Italy," by M. El Hachem et al., which was published in the July 1, 2015 issue of "Pharmaeconomics- Italian Research Articles.

  • Diagnosis and Surgical Management of Umbilical Hemangioma in a Lamb. Abubakar, A. A.; Sahabi, S. M.; Yakubu, A. S. // Intas Polivet;Jan-Jun2013, Vol. 14 Issue 1, p99 

    A month old male Ouda lamb was presented with abnormal ulcerative growth at the umbilicus. On physical examination, the mass was solid measured 2x2.5cm2 and ulcerative with foul smelling odor. Standard surgical excision of mass was successfully performed. Biopsy revealed proliferation of vessels...

  • Giant Hepatic Hemangioma Treated with Enucleation After Selective Portal Ven Embolisation. Tekin, Ahmet; Sahin, Mustafa; Küçükkartallar, Tevfik; Esen, Hasan // Erciyes Medical Journal / Erciyes Tip Dergisi;2009 Supplement 1, pS19 

    Hemangioma is the most common benign tumors of the liver and it is often asymptomatic. It is occur in all age but predominantly in women. They often do not need to be removed or treated. Conservative treatment of the liver hemangioma is preferred because of the minimal risk of complications....

  • Sclerotherapy for the Treatment of Infantile Hemangiomas. Grover, Chander; Khurana, Ananta; Bhattacharya, Sambit N. // Journal of Cutaneous & Aesthetic Surgery;Jul2012, Vol. 5 Issue 3, p201 

    Sclerotherapy is a simple, technically easy and effective mode of treatment for infantile hemangiomas (IH). It acts by blocking the growth of actively proliferating lesions, by targeting their vascularity accelerating their regression. Polidocanol is a commonly used sclerosant. We report two...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics